You have 1 free disease view remaining today. Register for more view, it is 100% free →
obsolete renal pelvis and ureter transitional cell cancer
Description
Obsolete Renal Pelvis and Ureter Transitional Cell Cancer
Transitional cell carcinoma (TCC) that arises from the urothelial lining of the renal pelvis is a rare type of cancer. It was previously known as transitional cell cancer of the renal pelvis and ureter, but this term is now considered obsolete.
Characteristics
- This type of cancer begins in the transitional cells that line the renal pelvis and/or the ureter.
- The lining of the renal pelvis is made up of transitional cells that are able to bend and stretch without breaking. When cancer grows in these pliable cells, it’s called transitional cell carcinoma (TCC).
- Transitional cell cancer of the renal pelvis accounts for only 7% of all kidney tumors, and transitional cell cancer of the ureter accounts for only 4% of upper urinary tract tumors.
Causes
- The exact causes of transitional cell cancer of the renal pelvis and ureter are not well understood.
- However, certain changes to the way transitional cells in the renal pelvis and ureters function, especially how they grow and divide into new cells, can lead to this type of cancer.
Symptoms
- Symptoms of transitional cell cancer of the renal pelvis and ureter may include:
- Blood in the urine
- Back pain
- Cramps in the side or back
- Fatigue
Treatment
- Treatment for transitional cell cancer of the renal pelvis and ureter typically involves surgery, chemotherapy, radiation, targeted therapy, and may involve a urology, urologic oncology program, prostate & urologic cancers program.
Stages
- The stages of renal pelvis and ureter cancer are:
- Stage 0: Abnormal cells in tissue lining the renal pelvis or ureter (papillary carcinoma or carcinoma in situ)
- Stage 1: Cancer spreads through the lining of the renal pelvis and/or ureter into a layer of connective tissue.
References
- [3] Upper tract urothelial carcinoma (UTUC) accounts for 5% of urothelial carcinomas (UCs), the estimated annual incidence being 1–2 cases per 100,000 inhabitants.
- [10] Transitional cell cancer of the renal pelvis and ureter is caused by certain changes to the way transitional cells in the renal pelvis and ureters function, especially how they grow and divide into new cells.
- [12] Transitional cell cancer of the renal pelvis accounts for only 7% of all kidney tumors, and transitional cell cancer of the ureter accounts for only 4% of upper urinary tract tumors.
Additional Characteristics
- Transitional cell carcinoma (TCC) that arises from the urothelial lining of the renal pelvis is a rare type of cancer.
- Symptoms may include: Blood in the urine, Back pain, Cramps in the side or back, Fatigue
- Treatment typically involves surgery, chemotherapy, radiation, targeted therapy, and may involve a urology, urologic oncology program, prostate & urologic cancers program.
- or ureter into a layer of connective tissue.
Signs and Symptoms
Early Signs and Symptoms
The early signs and symptoms of renal pelvis and ureter transitional cell cancer (TCC) can be subtle and may not always be present in the early stages of the disease. However, when they do occur, they can include:
- Blood in the urine (hematuria) [5][10]
- Pain in the back or side that does not go away [2][13]
- Cramps in the side or back [9]
- Fatigue [10]
Other Possible Symptoms
As the disease progresses, other symptoms may develop, including:
- A lump in the abdomen (tummy) or side [2]
- Dark, rusty, or brown-colored urine [2]
- Painful urination or difficulty starting to urinate [11]
Importance of Early Detection
It's essential to note that early detection and treatment can significantly improve the chances of recovery. If you experience any of these symptoms, it's crucial to consult a healthcare professional for proper evaluation and diagnosis.
References:
[1] Not available in context [2] Context 2: a change in the colour of your urine to dark, rusty or brown; a lump in your abdomen (tummy) or side; pain in your side or lower back that does not go away ... [5] by Y Nagasako · 2017 · Cited by 5 — Gross or microscopic hematuria was the principal sign of renal pelvic or ureteral cancer and was present in more than 75% of patients at diagnosis [5]. [9] by T Laskowski · 2024 — The most common symptoms of. TCC in kidney transplant recipients are painless gross hematuria and pyuria; other presentations of TCC include ... [10] •A cancer that begins in cells in the renal pelvis and ureter, which are part of the upper urinary tract • Symptoms include blood in the urine, back pain, cramps in the side or back, fatigue • Treatment includes surgery, chemotherapy, radiation, targeted therapy • Involves urology, urologic oncology program, prostate & urologic cancers program [11] Transitional cell cancer of the renal pelvis and ureter treatment is primarily surgery. In the case that the cancer has spread or come back, chemotherapy is sometimes used. ... A personal history of bladder cancer and smoking can increase the risk of transitional cell cancer of the renal pelvis and ureter. Signs and symptoms of transitional ... [13] Transitional cell cancer (kidney cancer) of the renal pelvis and ureter is a disease in which malignant cells form from transitional cells in the renal pelvis and ureter. Signs and symptoms may be absent in the early stages of the disease; however, when they do occur, the following may happen: blood in the urine, pain in the back that is ...
Additional Symptoms
- Blood in the urine (hematuria)
- Cramps in the side or back
- A lump in the abdomen (tummy) or side
- Painful urination or difficulty starting to urinate
- pain
- fatigue
- dark urine
Diagnostic Tests
Diagnostic Tests for Obsolete Renal Pelvis and Ureter Transitional Cell Cancer
Transitional cell cancer of the renal pelvis and ureter is a rare urinary tract cancer that typically affects adults ages 65 and older. To diagnose this condition, doctors will obtain a medical history, perform a physical exam, and order diagnostic tests.
Diagnostic Tests:
- Urinalysis may show blood in the urine [8].
- A complete blood count (CBC) may show anemia [8].
- Urine cytology (microscopic examination of cells) may reveal cancer cells [8].
- Computed tomography urography (CTU) has largely replaced excretion urography and is used to diagnose transitional cell cancer of the renal pelvis and ureter, especially in patients with haematuria [5].
- Gross examination and sampling should document the relationship of tumor to adjacent renal parenchyma, peripelvic fat, nearest soft tissue, and bladder cuff [6].
Imaging Studies:
- Computed tomography (CT) scans or magnetic resonance imaging (MRI) may be used to visualize the tumor and surrounding tissues.
- CTU is particularly useful in patients with haematuria and for upper urinary tract tumors.
Other Tests:
- Cystoscopy, a procedure where a flexible tube with a camera is inserted through the urethra to examine the bladder, may be performed if bladder cancer is suspected [7].
- Ureteroscopy can give detailed information on tumor localization, architecture, focality, and tumor size and is an essential step to establish the diagnosis of transitional cell carcinoma of the upper urinary tract [2].
Note: The diagnostic tests mentioned above are not exhaustive, and a comprehensive evaluation may involve other tests and procedures.
References: [1] - Transitional cell cancer of the renal pelvis accounts for only 7% of all kidney tumors, and transitional cell cancer of the ureter accounts for only 4% of upper urinary tract tumors [11]. [2] - Ureteroscopy can give detailed information on tumor localization, architecture, focality, and tumor size and is an essential step to establish the diagnosis of transitional cell carcinoma of the upper urinary tract [2]. [5] - Computed tomography urography (CTU) has largely replaced excretion urography. Indications for CTU include patients with haematuria and for upper urinary tract tumors [5]. [6] - Gross examination and sampling should document the relationship of tumor to adjacent renal parenchyma, peripelvic fat, nearest soft tissue, and bladder cuff [6]. [7] - Cystoscopy, a procedure where a flexible tube with a camera is inserted through the urethra to examine the bladder, may be performed if bladder cancer is suspected [7]. [8] - Urinalysis may show blood in the urine. A complete blood count (CBC) may show anemia. Urine cytology (microscopic examination of cells) may reveal cancer cells [8]. [11] - Transitional cell cancer of the renal pelvis accounts for only 7% of all kidney tumors, and transitional cell cancer of the ureter accounts for only 4% of upper urinary tract tumors [11].
Additional Diagnostic Tests
- Ureteroscopy
- Urinalysis
- Cystoscopy
- Urine cytology
- A complete blood count (CBC)
- Computed tomography urography (CTU)
- Gross examination and sampling
Treatment
Based on the provided context, it appears that there are limited treatment options available for transitional cell cancer of the renal pelvis and ureter.
- Chemotherapy: While chemotherapy is a common treatment option for various types of cancers, its effectiveness in treating transitional cell cancer of the renal pelvis and ureter seems to be limited. According to search result [14], regional treatment involves placing chemotherapy or immunotherapy drugs directly into the renal pelvis or ureter, but this method may cause side effects.
- Immunotherapy: Search result [7] mentions atezolizumab as a first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma. However, its effectiveness specifically for transitional cell cancer of the renal pelvis and ureter is unclear.
- Targeted therapy: Search result [11] mentions targeted therapy as one of the treatment options for this type of cancer, but no specific details are provided.
It's worth noting that surgery, particularly nephroureterectomy, seems to be a more common treatment approach for transitional cell cancer of the renal pelvis and ureter. According to search result [15], most people with this condition undergo nephroureterectomy, which involves removing the affected part of the kidney and ureter.
In summary, while there are some treatment options available for transitional cell cancer of the renal pelvis and ureter, their effectiveness seems to be limited compared to other types of cancers. Further research is needed to determine the best course of treatment for this condition.
References:
[14] Regional treatment for transitional cell cancer of renal pelvis and ureter is a method of placing the chemotherapy or immunotherapy drug directly into the renal pelvis or the ureter to mainly affect cancer cells in those areas. [7] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, ... [15] Most people with transitional cell cancer of the renal pelvis and ureter undergo nephroureterectomy. Segmental resection of the ureter is a surgical procedure to remove the part of the ureter that contains cancer and some of the healthy tissue around it.
Recommended Medications
- Chemotherapy
- Targeted therapy
- Immunotherapy (with atezolizumab)
💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.
Differential Diagnosis
Additional Information
- oboInOwl#hasOBONamespace
- disease_ontology
- oboInOwl#id
- DOID:4009
- core#notation
- DOID:4009
- rdf-schema#label
- obsolete renal pelvis and ureter transitional cell cancer
- oboInOwl#hasExactSynonym
- Urothelial carcinoma of the renal Pelvis and Ureter
- owl#deprecated
- true
- 22-rdf-syntax-ns#type
- http://www.w3.org/2002/07/owl#Class
- rdf-schema#domain
- https://w3id.org/def/predibionto#has_symptom_10635
Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.
It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.